Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1

Paul A. Krogstad, Sophia Lee, George Johnson, Kenneth Stanley, James McNamara, John Moye, J. Brooks Jackson, Rosaura Aguayo, Arry Dieudonne, Margaret Khoury, Hermann Mendez, Sharon Nachman, Andrew Wiznia, Anita Ballow, Francesca Aweeka, Howard Max Rosenblatt, Lynette Perdue, Anne Frasia, Rita Jeremy, Martin AndersonAnthony Japour, Catherine Fields, Angie Farnsworth, Ronald Lewis, Steven Schnittman, Maria Gigliotti, Samuel Maldonaldo, Barbara Lane, Jaime E. Hernandez, Kathlenn Mohan, S. Fikrig, H. Moallem Swindell, H. Mendez, E. Handelsman, H. Bergin, R. Aguayo, W. I. Figueroa, E. J. Reyes, D. Storm, R. Stephens, P. Palumbo, A. Kovacs, M. Khoury, J. Homans, R. Kairam, M. Bamji, W. Biernick, K. Dorio, M. Chin, E. J. Abrams, E. Calo, M. Frere, S. Rana, H. Finke, P. Houston, A. Bonwit, A. Seda, E. Talatala, S. Gaur, D. Persaud, A. Ruff, S. Marvin, R. Yogev, K. Boyer, P. Lofton, A. Petru, T. Courville, V. R. Bonagura, S. J. Schuval, C. Colter, M. Davi, L. Romard, F. Giliotti, G. A. Weinberg, B. Murante, L. Lugo, Z. Rivera, I. Febo, H. Lischner, D. Conaway, Savita G Pahwa, R. Yogev, J. Englund, S. Pahwa, S. Bakshi, L. Rodriguez, S. Nesheim, J. Sleasman, A. J. Melvin, K. Mohan, L. M. Frenkel, K. McIntosh, M. Kelller, M. Lugo, M. Acebedo, M. Ramos, R. Rutstein, D. Schaible, Gwendolyn B Scott

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ≤400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.

Original languageEnglish
Pages (from-to)991-1001
Number of pages11
JournalClinical Infectious Diseases
Volume34
Issue number7
DOIs
StatePublished - Apr 1 2002

Fingerprint

Nelfinavir
Nevirapine
Ritonavir
Reverse Transcriptase Inhibitors
Nucleosides
HIV-1
Lamivudine
Stavudine
Viremia
Clinical Protocols
Protease Inhibitors
Pharmaceutical Preparations
Acquired Immunodeficiency Syndrome
Therapeutics
Clinical Trials
RNA
Pediatrics

ASJC Scopus subject areas

  • Immunology

Cite this

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. / Krogstad, Paul A.; Lee, Sophia; Johnson, George; Stanley, Kenneth; McNamara, James; Moye, John; Jackson, J. Brooks; Aguayo, Rosaura; Dieudonne, Arry; Khoury, Margaret; Mendez, Hermann; Nachman, Sharon; Wiznia, Andrew; Ballow, Anita; Aweeka, Francesca; Rosenblatt, Howard Max; Perdue, Lynette; Frasia, Anne; Jeremy, Rita; Anderson, Martin; Japour, Anthony; Fields, Catherine; Farnsworth, Angie; Lewis, Ronald; Schnittman, Steven; Gigliotti, Maria; Maldonaldo, Samuel; Lane, Barbara; Hernandez, Jaime E.; Mohan, Kathlenn; Fikrig, S.; Moallem Swindell, H.; Mendez, H.; Handelsman, E.; Bergin, H.; Aguayo, R.; Figueroa, W. I.; Reyes, E. J.; Storm, D.; Stephens, R.; Palumbo, P.; Kovacs, A.; Khoury, M.; Homans, J.; Kairam, R.; Bamji, M.; Biernick, W.; Dorio, K.; Chin, M.; Abrams, E. J.; Calo, E.; Frere, M.; Rana, S.; Finke, H.; Houston, P.; Bonwit, A.; Seda, A.; Talatala, E.; Gaur, S.; Persaud, D.; Ruff, A.; Marvin, S.; Yogev, R.; Boyer, K.; Lofton, P.; Petru, A.; Courville, T.; Bonagura, V. R.; Schuval, S. J.; Colter, C.; Davi, M.; Romard, L.; Giliotti, F.; Weinberg, G. A.; Murante, B.; Lugo, L.; Rivera, Z.; Febo, I.; Lischner, H.; Conaway, D.; Pahwa, Savita G; Yogev, R.; Englund, J.; Pahwa, S.; Bakshi, S.; Rodriguez, L.; Nesheim, S.; Sleasman, J.; Melvin, A. J.; Mohan, K.; Frenkel, L. M.; McIntosh, K.; Kelller, M.; Lugo, M.; Acebedo, M.; Ramos, M.; Rutstein, R.; Schaible, D.; Scott, Gwendolyn B.

In: Clinical Infectious Diseases, Vol. 34, No. 7, 01.04.2002, p. 991-1001.

Research output: Contribution to journalArticle

Krogstad, PA, Lee, S, Johnson, G, Stanley, K, McNamara, J, Moye, J, Jackson, JB, Aguayo, R, Dieudonne, A, Khoury, M, Mendez, H, Nachman, S, Wiznia, A, Ballow, A, Aweeka, F, Rosenblatt, HM, Perdue, L, Frasia, A, Jeremy, R, Anderson, M, Japour, A, Fields, C, Farnsworth, A, Lewis, R, Schnittman, S, Gigliotti, M, Maldonaldo, S, Lane, B, Hernandez, JE, Mohan, K, Fikrig, S, Moallem Swindell, H, Mendez, H, Handelsman, E, Bergin, H, Aguayo, R, Figueroa, WI, Reyes, EJ, Storm, D, Stephens, R, Palumbo, P, Kovacs, A, Khoury, M, Homans, J, Kairam, R, Bamji, M, Biernick, W, Dorio, K, Chin, M, Abrams, EJ, Calo, E, Frere, M, Rana, S, Finke, H, Houston, P, Bonwit, A, Seda, A, Talatala, E, Gaur, S, Persaud, D, Ruff, A, Marvin, S, Yogev, R, Boyer, K, Lofton, P, Petru, A, Courville, T, Bonagura, VR, Schuval, SJ, Colter, C, Davi, M, Romard, L, Giliotti, F, Weinberg, GA, Murante, B, Lugo, L, Rivera, Z, Febo, I, Lischner, H, Conaway, D, Pahwa, SG, Yogev, R, Englund, J, Pahwa, S, Bakshi, S, Rodriguez, L, Nesheim, S, Sleasman, J, Melvin, AJ, Mohan, K, Frenkel, LM, McIntosh, K, Kelller, M, Lugo, M, Acebedo, M, Ramos, M, Rutstein, R, Schaible, D & Scott, GB 2002, 'Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1', Clinical Infectious Diseases, vol. 34, no. 7, pp. 991-1001. https://doi.org/10.1086/338814
Krogstad, Paul A. ; Lee, Sophia ; Johnson, George ; Stanley, Kenneth ; McNamara, James ; Moye, John ; Jackson, J. Brooks ; Aguayo, Rosaura ; Dieudonne, Arry ; Khoury, Margaret ; Mendez, Hermann ; Nachman, Sharon ; Wiznia, Andrew ; Ballow, Anita ; Aweeka, Francesca ; Rosenblatt, Howard Max ; Perdue, Lynette ; Frasia, Anne ; Jeremy, Rita ; Anderson, Martin ; Japour, Anthony ; Fields, Catherine ; Farnsworth, Angie ; Lewis, Ronald ; Schnittman, Steven ; Gigliotti, Maria ; Maldonaldo, Samuel ; Lane, Barbara ; Hernandez, Jaime E. ; Mohan, Kathlenn ; Fikrig, S. ; Moallem Swindell, H. ; Mendez, H. ; Handelsman, E. ; Bergin, H. ; Aguayo, R. ; Figueroa, W. I. ; Reyes, E. J. ; Storm, D. ; Stephens, R. ; Palumbo, P. ; Kovacs, A. ; Khoury, M. ; Homans, J. ; Kairam, R. ; Bamji, M. ; Biernick, W. ; Dorio, K. ; Chin, M. ; Abrams, E. J. ; Calo, E. ; Frere, M. ; Rana, S. ; Finke, H. ; Houston, P. ; Bonwit, A. ; Seda, A. ; Talatala, E. ; Gaur, S. ; Persaud, D. ; Ruff, A. ; Marvin, S. ; Yogev, R. ; Boyer, K. ; Lofton, P. ; Petru, A. ; Courville, T. ; Bonagura, V. R. ; Schuval, S. J. ; Colter, C. ; Davi, M. ; Romard, L. ; Giliotti, F. ; Weinberg, G. A. ; Murante, B. ; Lugo, L. ; Rivera, Z. ; Febo, I. ; Lischner, H. ; Conaway, D. ; Pahwa, Savita G ; Yogev, R. ; Englund, J. ; Pahwa, S. ; Bakshi, S. ; Rodriguez, L. ; Nesheim, S. ; Sleasman, J. ; Melvin, A. J. ; Mohan, K. ; Frenkel, L. M. ; McIntosh, K. ; Kelller, M. ; Lugo, M. ; Acebedo, M. ; Ramos, M. ; Rutstein, R. ; Schaible, D. ; Scott, Gwendolyn B. / Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. In: Clinical Infectious Diseases. 2002 ; Vol. 34, No. 7. pp. 991-1001.
@article{6caf9182c0834b208459e71e24434221,
title = "Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1",
abstract = "The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41{\%}) of 41 subjects receiving d4T-NVP-RTV, 13 (30{\%}) of 44 receiving d4T-NVP-NFV, 21 (42{\%}) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52{\%}) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ≤400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.",
author = "Krogstad, {Paul A.} and Sophia Lee and George Johnson and Kenneth Stanley and James McNamara and John Moye and Jackson, {J. Brooks} and Rosaura Aguayo and Arry Dieudonne and Margaret Khoury and Hermann Mendez and Sharon Nachman and Andrew Wiznia and Anita Ballow and Francesca Aweeka and Rosenblatt, {Howard Max} and Lynette Perdue and Anne Frasia and Rita Jeremy and Martin Anderson and Anthony Japour and Catherine Fields and Angie Farnsworth and Ronald Lewis and Steven Schnittman and Maria Gigliotti and Samuel Maldonaldo and Barbara Lane and Hernandez, {Jaime E.} and Kathlenn Mohan and S. Fikrig and {Moallem Swindell}, H. and H. Mendez and E. Handelsman and H. Bergin and R. Aguayo and Figueroa, {W. I.} and Reyes, {E. J.} and D. Storm and R. Stephens and P. Palumbo and A. Kovacs and M. Khoury and J. Homans and R. Kairam and M. Bamji and W. Biernick and K. Dorio and M. Chin and Abrams, {E. J.} and E. Calo and M. Frere and S. Rana and H. Finke and P. Houston and A. Bonwit and A. Seda and E. Talatala and S. Gaur and D. Persaud and A. Ruff and S. Marvin and R. Yogev and K. Boyer and P. Lofton and A. Petru and T. Courville and Bonagura, {V. R.} and Schuval, {S. J.} and C. Colter and M. Davi and L. Romard and F. Giliotti and Weinberg, {G. A.} and B. Murante and L. Lugo and Z. Rivera and I. Febo and H. Lischner and D. Conaway and Pahwa, {Savita G} and R. Yogev and J. Englund and S. Pahwa and S. Bakshi and L. Rodriguez and S. Nesheim and J. Sleasman and Melvin, {A. J.} and K. Mohan and Frenkel, {L. M.} and K. McIntosh and M. Kelller and M. Lugo and M. Acebedo and M. Ramos and R. Rutstein and D. Schaible and Scott, {Gwendolyn B}",
year = "2002",
month = "4",
day = "1",
doi = "10.1086/338814",
language = "English",
volume = "34",
pages = "991--1001",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1

AU - Krogstad, Paul A.

AU - Lee, Sophia

AU - Johnson, George

AU - Stanley, Kenneth

AU - McNamara, James

AU - Moye, John

AU - Jackson, J. Brooks

AU - Aguayo, Rosaura

AU - Dieudonne, Arry

AU - Khoury, Margaret

AU - Mendez, Hermann

AU - Nachman, Sharon

AU - Wiznia, Andrew

AU - Ballow, Anita

AU - Aweeka, Francesca

AU - Rosenblatt, Howard Max

AU - Perdue, Lynette

AU - Frasia, Anne

AU - Jeremy, Rita

AU - Anderson, Martin

AU - Japour, Anthony

AU - Fields, Catherine

AU - Farnsworth, Angie

AU - Lewis, Ronald

AU - Schnittman, Steven

AU - Gigliotti, Maria

AU - Maldonaldo, Samuel

AU - Lane, Barbara

AU - Hernandez, Jaime E.

AU - Mohan, Kathlenn

AU - Fikrig, S.

AU - Moallem Swindell, H.

AU - Mendez, H.

AU - Handelsman, E.

AU - Bergin, H.

AU - Aguayo, R.

AU - Figueroa, W. I.

AU - Reyes, E. J.

AU - Storm, D.

AU - Stephens, R.

AU - Palumbo, P.

AU - Kovacs, A.

AU - Khoury, M.

AU - Homans, J.

AU - Kairam, R.

AU - Bamji, M.

AU - Biernick, W.

AU - Dorio, K.

AU - Chin, M.

AU - Abrams, E. J.

AU - Calo, E.

AU - Frere, M.

AU - Rana, S.

AU - Finke, H.

AU - Houston, P.

AU - Bonwit, A.

AU - Seda, A.

AU - Talatala, E.

AU - Gaur, S.

AU - Persaud, D.

AU - Ruff, A.

AU - Marvin, S.

AU - Yogev, R.

AU - Boyer, K.

AU - Lofton, P.

AU - Petru, A.

AU - Courville, T.

AU - Bonagura, V. R.

AU - Schuval, S. J.

AU - Colter, C.

AU - Davi, M.

AU - Romard, L.

AU - Giliotti, F.

AU - Weinberg, G. A.

AU - Murante, B.

AU - Lugo, L.

AU - Rivera, Z.

AU - Febo, I.

AU - Lischner, H.

AU - Conaway, D.

AU - Pahwa, Savita G

AU - Yogev, R.

AU - Englund, J.

AU - Pahwa, S.

AU - Bakshi, S.

AU - Rodriguez, L.

AU - Nesheim, S.

AU - Sleasman, J.

AU - Melvin, A. J.

AU - Mohan, K.

AU - Frenkel, L. M.

AU - McIntosh, K.

AU - Kelller, M.

AU - Lugo, M.

AU - Acebedo, M.

AU - Ramos, M.

AU - Rutstein, R.

AU - Schaible, D.

AU - Scott, Gwendolyn B

PY - 2002/4/1

Y1 - 2002/4/1

N2 - The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ≤400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.

AB - The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ≤400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.

UR - http://www.scopus.com/inward/record.url?scp=0036532103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036532103&partnerID=8YFLogxK

U2 - 10.1086/338814

DO - 10.1086/338814

M3 - Article

C2 - 11880966

AN - SCOPUS:0036532103

VL - 34

SP - 991

EP - 1001

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -